According to Melbourn Scientific the company has recently been awarded a Manufacturer’s/Importer’s Authorization (MIA), which allows it to act as a testing and release site for the EU. Melbourn is among the largest suppliers of OINDP-focused contract research in Europe and offers services from formulation development through clinical trials manufacturing.
Melbourn CEO Mark Hammond commented, “The EU is an important market and with the Manufacturer’s/Importer’s Authorization, we are able to import commercial products which have been manufactured outside the EU and to test them prior to release for sale within the EU/EEA.”
The company says that the MIA will enable it to offer OINDP research services in response to global demand. Hammond explained, “We are seeing an increase in interest from companies across Asia and India who are looking for CRO partners with proven expertise in supporting inhaled and intranasal programs. Inhalation Asia will be the first time we have exhibited in the Far East and we are looking forward to the experience.”
Read the Melbourn press release.
